Researchers ofUniversità Campus Bio-Medico di Roma, led by prof. Mauro Maccarrone, have demonstrated for the first time that patients suffering from this serious pathology – the second cause of hospitalization, after childbirth, in Italy and which affects 1,2% of people between 18 and 40 years – show reduced levels of resolvin D1, lipid molecule capable of stopping the persistent inflammatory state of the heart

The research, published in the scientific journal FASEB Journal, clarified that in these subjects there is also a reduced expression of the receptor capable of mediating the biological effects of resolvin D1. Which, therefore, is a candidate to become a new bio-marker of the disease in the blood and a more effective target of therapies to defeat it

 

Rome, 20 September 2018 - I. researchers ofUniversità Campus Bio-Medico di Roma have discovered and demonstrated, first, role decisive factor of a lipid molecule, the resolvin D1, in the onset of chronic heart failure, a serious condition that manifests itself in the inability of the heart to pump blood adequately. A disease that in Italy represents the second cause of hospitalization, after childbirth, affects the 10% of the population over 75 - as well as 1,2% of subjects between 18 and 40 years old– and occurs in a quarter of heart attack patients within four years of the event.

Huge le social consequences for those who suffer from it: difficulty in making physical efforts, struggles just to climb a flight of stairs, swelling in the lower limbs, but also dizziness or constipation. The disease is discovered with the electrocardiogram and the cardiological examination, but is certified by the eco-heart, which quantifies the (reduced) ability to contract the muscle cardiac. At that point, the risk of episodes of decompensation is always around the corner, up to the urgent need for one transplanting.

Scientists have been able to highlight the reduced presence of resolvin D1 in the blood of the sick. "A defect - emphasizes the professor Mauro Maccarrone, Professor of Biochemistry at the Faculty of Medicine and Surgery of UCBM e principal investigator of research – which originated from a reduced ability of the body's immune cells to synthesize this particular lipid, so much so that the less it is present, the more serious the pathological condition of the subject is".

The study, recently published in the scientific journal FASEB Journal, was conducted in collaboration with the Complex Operational Unit of Geriatrics of the University Hospital Biomedical Campus directed by the professor Raffaele Antonelli Incalzi and saw the international expert on resolvin as its first signing Valerio Chiurchiù, co-head of research and in the Maccarrone working group.

Experts have also shown that the restoration of this resolvin – simulated through the in vitro treatment of T lymphocytes isolated from the blood of patients – however, it is not enough to control inflammatory responses that originate in the heart muscle: this is because it has been discovered that the reduced levels of resolvin D1 are accompanied, in chronic heart failure, even from one reduced expression of the receptor responsible for mediating its biological effects.

The study therefore revealed the presence of a defect in the process of resolving inflammation, that generates or is associated with chronic heart failure. By better controlling the molecules capable of 'treating' this inflammation, therefore, they could open new possible treatment scenarios. "All that – Maccarrone confirms – suggests that resolvins could represent a new biomarker plasma for this heart disease. Not only that: they could also become a potential therapeutic target to develop, in the near future, more effective drugs than those available today".

 

Chiurchiù V, Leuti A, Saracini S, Fontana D, Finamore P, Giua R, Padovini L, Incalzi RA, Maccarrone M. Resolution of inflammation is altered in chronic heart failure and entails a dysfunctional responsiveness of T lymphocytes. FASEB J. 2018 Jul 27:fj201801017R. doi: 10.1096/fj.201801017R.